Soligenix, Inc. (SNGX) 10-Q Summary
Business Context and Reporting Period
Company: Soligenix, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: A biopharmaceutical company with two segments: Specialized BioTherapeutics (developing synthetic hypericin and dusquetide) and Public Health Solutions (vaccines for biodefense). The company operates as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenues | $0 | $0 |
| Net Loss | $(4,812,319) | $(5,653,244) |
| Net Loss Per Share (Basic/Diluted) | $(0.37) | $(1.79) |
| Operating Expenses | $4,984,301 | $5,790,387 |
| Research & Development | $2,756,391 | $3,618,694 |
| General & Administrative | $2,227,910 | $2,171,693 |
| Cash and Cash Equivalents (End of Period) | $9,811,141 | $5,097,670 |
| Net Cash Used in Operating Activities | $(4,064,414) | $(4,588,835) |
| Net Cash Provided by Financing Activities | $5,939,402 | $1,870,304 |
| Total Assets | $10,499,470 | $5,760,647 |
| Total Liabilities | $3,853,913 | $3,943,396 |
| Shareholders' Equity | $6,645,557 | $1,828,951 |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by $840,925 (14.9%) compared to the prior year period, primarily driven by a reduction in R&D expenses following the termination of the HyBryte™ (SGX301) development program.
- R&D Expense Decline: R&D expenses dropped $862,303 due to the wind-down of the FLASH2 trial and completion of the Phase 2 study for SGX945 (Behçet's Disease).
- Capital Raise: The company significantly increased cash reserves through an At-Market (ATM) issuance agreement, selling approximately 11.5 million shares for gross proceeds of ~$6.04 million during the six-month period.
- Share Count Increase: Weighted average shares outstanding increased significantly from ~3.2 million (2025) to ~13.1 million (2026), diluting per-share loss but improving liquidity.
Guidance, Outlook, Risks, and Unusual Items
- Program Termination: In June 2026, the Board terminated the HyBryte™ (SGX301) development program for Cutaneous T-Cell Lymphoma after the Data Monitoring Committee recommended halting the Phase 3 FLASH2 trial for futility. Estimated wind-down charges are ~$70,000.
- Going Concern Warning: Management has raised "substantial doubt" about the company's ability to continue as a going concern. While cash runway is projected to extend into Q2 2028, this relies on continued ATM sales and securing additional capital or strategic transactions, none of which are currently committed.
- Nasdaq Compliance: The company received a notice of non-compliance with the $1.00 minimum bid price requirement on June 10, 2026. It has 180 days (until December 7, 2026) to regain compliance or face delisting.
- Future Strategy: Focus remains on advancing SGX302 (psoriasis), SGX945 (Behçet's Disease), and SGX942 (oral mucositis), alongside government-funded Public Health Solutions (RiVax and filovirus vaccines).
- Unusual Items: Recorded a $58,443 gain on the extinguishment of vendor liabilities.
Investor Verification Checklist
- Liquidity Runway: Verify the accuracy of the Q2 2028 cash runway projection given the "substantial doubt" disclosure and reliance on uncommitted ATM sales.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by December 7, 2026, to avoid delisting.
- ATM Capacity: Confirm remaining capacity under the Rodman Sales Agreement (approx. $2.4 million as of July 31, 2026) and the pace of future issuances.
- Pipeline Progress: Track the status of the Phase 2a trial for SGX302 (psoriasis) and the design of the second Phase 3 trial for SGX942 (oral mucositis), which requires a partner.
- Government Funding: Assess the likelihood of securing new government grants for the Public Health Solutions segment, which is fully funded by external sources.